Faricimab eye injections and kidney function in diabetes

This study compares two injectable medications (faricimab and biosimilar ranibizumab) used to treat diabetic retinopathy, a serious eye condition that can cause vision loss in people with diabetes. The trial will measure how well each medication works and track specific markers in your eye to understand treatment response.

This study tests a treatment for diabetic macular edema (swelling in the back of the eye caused by diabetes) in people who have not had eye injections before. It aims to see if the treatment can improve vision.

This trial tests an eye injection called OLN324 for diabetic macular edema, a condition where fluid builds up in the retina and blurs vision. The treatment aims to improve vision and reduce swelling in the eye.

This study tests whether one eye injection (aflibercept) works better than another (bevacizumab) for people with diabetic macular edema. Both are already used for this condition, and the goal is to see which provides better vision improvement.

This study tests an experimental eye injection (OLN324) for people with diabetic macular edema, a condition where swelling in the back of the eye causes vision loss. The goal is to see if the injection can improve vision.

This study observes the effects of a drug called faricimab (given as eye injections) on people with wet age-related macular degeneration (AMD), a condition causing rapid vision loss from abnormal blood vessels leaking fluid in the back of the eye. It aims to see how well the drug works when given in a specific schedule and to monitor safety and outcomes over time. This is an observational study, so you would receive the treatment as part of your normal care, and the research team will collect data.